Table 1.
Patient characteristics before denosumab therapy
| Characteristic | TNF group (n=44) |
TCZ group (n=8) |
ABT group (n=14) |
|---|---|---|---|
| Age (years) | 67.5±1.0 | 67.6±2.6 | 70.4±2.2 |
| Gender (F:M) | 44:0 | 8:0 | 14:0 |
| BMI (kg/m2) | 20.5±0.5 | 21.6±1.6 | 20.4±1.1 |
| Disease duration (years) | 5.9±0.7 | 6.7±1.0 | 6.1±0.9 |
| Biologic DMARDs (n) | |||
| Infliximab | 14 | ||
| Etanercept | 15 | ||
| Adalimumab | 7 | ||
| Golimumab | 6 | ||
| Certolizumab pegol | 2 | ||
| Methotrexate use (n) | 39 | 5 | 10 |
| Methotrexate dose (mg/week) | 7.3±0.5 | 8.4±1.5 | 7.3±1.2 |
| Prednisolone use (n) | 10 | 4 | 5 |
| Prednisolone dose (mg/day) | 6.1±1.1 | 5.0±0.7 | 6.2±1.0 |
| DAS28CRP | 3.4±0.1 | 3.3±0.6 | 3.5±0.4 |
| CDAI | 13.3±1.2 | 14.9±3.8 | 13.9±2.5 |
| HAQ-DI | 0.9±0.1 | 1.0±0.3 | 1.1±0.4 |
| MMP-3 (IU/mL) | 93.1±22.5 | 85.0±16.7 | 94.5±21.9 |
| Serum albumin-corrected calcium (mg/dL) | 9.4±0.1 | 9.4±0.1 | 9.3±0.1 |
| Serum phosphorus (mg/dL) | 3.4±0.1 | 3.4±0.1 | 3.4±0.1 |
| Serum BAP (μg/L) | 14.7±1.2 | 13.6±2.1 | 14.1±1.8 |
| Serum TRACP-5b (mU/dL) | 280.6±23.7 | 245.8±53.5 | 249.8±42.1 |
| Urinary NTX (nmol BCE/mmol/CRE) | 42.3±4.6 | 42.4±9.9 | |
| Serum whole PTH (pg/mL) | 24.0±2.1 | 21.3±2.7 | 22.1±2.4 |
| Serum 1,25(OH)2D3 (pg/mL) | 43.2±2.5 | 34.8±5.4 | 41.2±4.2 |
| BP use (n) | 29 | 5 | 8 |
| BP period (years) | 4.3±0.3 | 4.6±0.9 | 4.5±0.6 |
| Lumbar 1–4 BMD (g/cm2) | 0.777±0.02 | 0.783±0.06 | 0.773±0.06 |
| Total hip BMD (g/cm2) | 0.575±0.02 | 0.566±0.04 | 0.580±0.04 |
Abbreviations: ABT, abatacept; BAP, bone-specific alkaline phosphatase; BMD, bone mineral density; BMI, body mass index; BP, bisphosphonate; CDAI, Crohn’s disease activity index; DAS28CRP, disease activity score 28 C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; F, female; HAQ-DI, health assessment questionnaire disability index; M, male; MMP-3, matrix metalloproteinase-3; NTX, type I collagen cross-linked N-telopeptide; PTH, parathyroid hormone; TCZ, tocilizumab; TNF, tumor necrosis factor; TRACP-5b, tartrate-resistant acid phosphatase 5b.